Novartis Global Health & Sustainability, East Hanover, New Jersey, United States.
Sickle Cell Foundation of Ghana, Accra, Ghana.
Semin Hematol. 2023 Sep;60(4):226-232. doi: 10.1053/j.seminhematol.2023.06.001. Epub 2023 Jul 7.
Novartis, a global medicines company, and the Sickle Cell Foundation of Ghana (SCFG), an advocacy organization, have endeavored to support the implementation of global best practices in the care of people living with sickle cell disease (SCD) in Africa, and to address unmet needs relating to this condition on the continent. Beginning in 2019, a multifaceted SCD program was implemented in Ghana through a public-private partnership involving the government of Ghana, the SCFG, Novartis, and other partners. A key component of the program involved expanding the reach of hydroxyurea (HU), the only approved disease-modifying generic treatment for SCD, in ways that would promote sustainable access. The program helped to raise the profile of SCD in Ghana and, in 2022, the government adopted HU into its National Health Insurance Scheme. Features of the effort in Ghana are now being expanded to other countries in Africa through cocreated programs with in-country partners. This article reviews the program's history, progress, challenges, and lessons learned.
诺华公司是一家全球性制药公司，加纳镰状细胞基金会（SCFG）是一个倡导组织，双方共同努力支持在非洲实施镰状细胞病（SCD）患者护理方面的全球最佳实践，并解决该疾病在非洲大陆面临的未满足需求。从 2019 年开始，通过加纳政府、SCFG、诺华公司和其他合作伙伴之间的公私合作伙伴关系，在加纳实施了一个多方面的 SCD 计划。该计划的一个关键组成部分涉及扩大羟基脲（HU）的覆盖范围，HU 是唯一获得批准的 SCD 疾病修正治疗药物，这将促进可持续获得治疗的机会。该计划提高了 SCD 在加纳的知名度，并且在 2022 年，加纳政府将 HU 纳入了国家健康保险计划。该计划在加纳的举措特点正在通过与国内合作伙伴共同创建的项目在非洲其他国家得到扩展。本文回顾了该计划的历史、进展、挑战和经验教训。
